Vaxxas makes David Hoey its first CEO
This article was originally published in Scrip
Vaxxas, a privately-held biotech company focused on commercialising its vaccine platform Nanopatch, has appointed David Hoey its first CEO. Mr Hoey most recently served as a board member and vice-president of business development for PathoGenetix.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.